Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
By using fixed charges to engineer a strong electroosmotic flow, we achieve the unidirectional transport of natural polypeptides across nanopores. Our approach enables native proteins to be transported enzymatically and non-enzymatically in the absence of denaturant and electrophoretic tags, with potential applications for protein sequencing.
Some 700 approved therapies in the United States — roughly a third of all drugs on the market — target G-protein-coupled receptors (GPCRs). Now advances in high-throughput and structure-based screening are sparking a second golden age of GPCR-based drug discovery.
A new era of brain-penetrant therapies is opening up, as companies hook up drugs to transferrin receptors or use viral capsids to hitch a ride into previously inaccessible regions.
Drugs commonly used in rheumatology, the JAK inhibitors, are opening up treatment options for people with autoimmune-driven hair loss, and new mechanistic knowledge is also helping scientists tackle androgenic alopecia, the commonest cause of baldness.
